Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$120.04
Open:$118.96
Day's Low:$117.27
Day's High:$121.05
Bid / Ask:-
Market Cap:23.97B
Enterprise Value:20.65B
52-Week Range
52-Week Low:$89.25
52-Week High:$132.60
Current position in 52-week range
52w Low-52w High
50-Day Avg:$120.33
200-Day Avg:$108.13
Volume
Volume Today:2,171,743
Avg Volume (3m):1,610,471
Avg Volume (10d):2,039,600
52-Week Change:+16.63%
vs S&P 500, 52 weeks:-
Beta:0.78
Valuation Multiples
P/E (trailing):62.55
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.
P/E (forward):13.58
PEG Ratio:10.82
Price / Book:4.25
Price / Sales (TTM):3.99
EV / Revenue:3.44
EV / EBITDA:10.15
Dividends
Current yield:-
Annual Dividend Rate:-
Dividend Trailing:$0.00
Yield Trailing:0.00%
5-Year Avg Yield:-
Payout Ratio:0.00%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):6.01B
Gross Profit:3.37B
EBITDA:2.04B
Net Income (TTM):403.41M
Rev Growth (YoY):+14.00%
Earnings Growth (YoY):-
Quarterly earnings growth (YoY):-
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$1.88
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$8.66
Revenue Per Share:$30.04
Cash Per Share:-
Book Value:$27.66
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:3.85B
Total Debt:37.41M
Net Debt (Debt - Cash):−3.82B (net cash)
Debt / Equity:0.66%
Current Ratio:3.84
Quick Ratio:3.54
Cash Flows
Operating Cash Flow:744.99M
Free Cash Flow (FCF):1.29B
FCF Yield (FCF / Market Cap):-
Enterprise Value:20.65B
EV / Revenue:3.44
EV / EBITDA:10.15
Profitability
ROE (Return on Equity):7.84%
ROA (Return on Assets):17.78%
P/E (trailing):62.55
P/E (forward):13.58
Price / Book:4.25
PEG Ratio:10.82
52-Week Change:+16.63%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$1.88
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$8.66
P/E (forward):13.58
PEG Ratio:10.82
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$30.04
Cash Per Share:-
Book Value:$27.66
Cash Flows (TTM)
Free Cash Flow:1.29B
Operating Cash Flow:744.99M
EBITDA:2.04B
Total Revenue (TTM):6.01B
Net Income (TTM):403.41M
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:203,832,492
Float (free shares):171,555,617
Short interest (shares):10,025,354
Short % of float:-
Short Ratio (days to cover):5.61
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Incyte Corporation (INCY) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Principal Financial Officer, VP of Finance & Chief Accounting Officer
47
529,848
Dr. Steven H. Stein M.D.
Executive VP, Head of Late-stage Development & Chief Medical Officer
58
1.57M
Mr. Mohamed Khairie Issa
Executive Vice President & Head of U.S. Commercial
42
2.27M
Mr. Suketu P. Upadhyay
Executive VP & CFO
56
-
Mr. Michael James Morrissey
Executive VP & Head of Global Technical Operations
61
-
Ms. Alexis Smith
VP & Head of Investor Relations
-
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
Incyte Corporation (INCY): Quantitative Analysis
Incyte Corporation (INCY) — Healthcare — Biotechnology. INCY is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, INCY has returned +19.1% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
INCY ranks 310 of 461 on today's multifactor score, and 42 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 0.37, ranked 150 of 494); its weakest is growth (Z -0.73, ranked 465 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
Incyte has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Oct 29, 2026). INCY earnings dates and times, quarter by quarter →
What is Incyte's P/E ratio?
Incyte's P/E (price over earnings per share for the last twelve months) is 62.5 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Incyte is above its sector median. Healthcare stocks, company by company →
Where does Incyte rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, Incyte ranks 310 of 461, and 42 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have Incyte insiders bought or sold shares?
SEC Form 4 shows no open-market purchase of Incyte shares from August 2025 through Nov 3, 2026. The latest sale was on Oct 15, 2026, by an officer, for $298k. In total, from August 2025 through Nov 3, 2026: 0 purchases and 40 sales by directors, officers and large shareholders. All INCY insider trades →
What sector is Incyte in, and which index?
Incyte is classified in the Healthcare sector (industry: Biotechnology), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.